Pfizer Inc. PFE today announced that Quillivant XR™ (methylphenidate
hydrochloride) CII for extended-release oral suspension is now available in
the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD).
Quillivant XR is the first once-daily, extended-release liquid methylphenidate
for ADHD and is now available by prescription.
“In order to effectively treat patients with chronic conditions such as ADHD,
it is important to consider individual patient needs, including options for
medication administration,” said Ann Childress, M.D., president of the Center
for Psychiatry and Behavioral Medicine, Las Vegas, who was an investigator in
the Quillivant XR laboratory classroom study. “As the first once-daily,
extended-release liquid medication for patients with ADHD, Quillivant XR
represents a new alternative to other ADHD treatments.”
Quillivant XR was approved by the U.S. Food and Drug Administration (FDA) on
September 27, 2012 for the treatment of ADHD in patients aged 6 years and
above. The efficacy of Quillivant XR was evaluated in a randomized,
double-blind, placebo-controlled, crossover, multicenter, laboratory classroom
study of 45 children with ADHD. Quillivant XR significantly improved ADHD
symptoms compared to placebo at the primary endpoint of four hours post-dose,
and in a secondary analysis, showed significant improvement at every time
point measured, from 45 minutes to 12 hours after dosing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in